Fanny Rabuel
Rare Disease Business Lead at Alnylam Pharmaceuticals | France
Fanny Rabuel’s Email & Phone Number
VerifiedFree account · No credit card · 5 profiles/month
ContactOut Insights • AI Generated
Fanny Rabuel Daumas serves as the Rare Disease Business Lead at Alnylam Pharmaceuticals, directing business operations within the French pharmaceutical sector. She holds a degree from Sciences Po Paris, providing academic grounding for her corporate role. Her work supports the biopharmaceutical group’s RNA interference therapeutic platform, which achieved the critical milestone of securing approval for the world’s first such medicine in 2018.
BEST APPROACH TO REACH Fanny Rabuel
Reach out via LinkedIn InMail with a concise proposal focused on rare disease commercialization strategies or biopharma partnerships tailored to the French market.
Rare Disease Business Lead at Alnylam Pharmaceuticals in September 2024 - Present
Regional Sales Manager (First Line Manager) at Novartis Oncology in September 2021 - March 2024
Cell & Gene Therapy Network Manager at Novartis Oncology in June 2018 - August 2021
Hematology Hospital Sales Representative at Novartis Oncology in December 2012 - May 2018
Exjade Senior Brand Manager at Novartis Oncology in September 2010 - November 2012
Femara Brand Manager at Novartis Oncology in April 2008 - September 2010
Business Development Officer at Sanofi-aventis Vietnam in March 2007 - February 2008
International Junior Brand Manager Lovenox at Sanofi in January 2005 - December 2006
Product Manager Assistant & Market Research Assistant Ajax at Colgate Palmolive in February 2004 - July 2004
Chargée de communication interne at Nestlé in January 2003 - June 2003
Communication and Press Relations at OJ Perrin in January 2001 - December 2001
Sciences Po Paris, Master's degree, July 2026
Ecole Supérieure du Commerce Extérieur (ESCE), Master's degree, July 1999 to July 2026
SILENCE DISEASE. AMPLIFY LIFE.™ Alnylam is a leading independent biopharmaceutical company and the pioneer in RNA interference (RNAi) therapeutics – a revolutionary approach to treating diseases which “silences” the genes that cause or contribute to them. Founded in 2002 by a group of distinguished researchers and biotech leaders, Alnylam’s work over more than two decades has yielded the critical breakthroughs and advancements that have made the field of (RNAi) therapeutics possible. In 2018, our first commercial medicine, and the world’s first RNAi therapeutic was approved. Since then, five more Alnylam-developed medicines have been approved and we’re hard at work developing new therapies to treat both rare and prevalent diseases. We are a global and diverse company of 2,600+ people. We pride ourselves on fostering a fun, inclusive and dynamic work environment where employees can recognize their fullest potential. That's why we’re consistently ranked as a top employer by The Boston Globe (2015-24), Science Magazine (2018-25), Fast Company (Best Workplaces for Innovators 2020-25) and LinkedIn (2024). We are based in Cambridge, Massachusetts (U.S.), with offices throughout North America, Europe, Asia, and South America. See our social media community guidelines: https://bit.ly/2FcRhJy. Please note: If you wish to report an adverse event or product complaint, please email [email protected] or you may call us using the following telephone numbers: for North America, 877.ALNYLAM (877.256.9526), for Europe, +31 20 369 7861 Fraudulent Recruitment Activity Be aware of the potential for scams and fraudulent recruitment activity from individuals claiming to represent Alnylam Pharmaceuticals. Alnylam never conducts its interview process via messaging apps, freelance sites, or social media platforms. Alnylam team members only communicate with potential candidates through an official Alnylam email address ending in "@alnylam.com."
Discover more about Alnylam Pharmaceuticals
Biotechnology & GMP
Manufacturing Associate at Alnylam Pharmaceuticals
(January 2025 – Present)
Regulatory Affairs Post-Doctoral Fellow at Alnylam Pharmaceuticals | 2024 SMDP Biotech Scholar
Pharmacy Intern at Spaulding Rehabilitation Hospital
(January 2022 – Present)
Manager, US Benefits at Alnylam Pharmaceuticals
Manager, US Benefits at Alnylam Pharmaceuticals
(December 2021 – Present)
Pharma & Biotech | Project Manager | Medical & Commercial Operations
Executive Assistant, Medical Affairs International & Global at Alnylam Pharmaceuticals
(November 2025 – Present)
Senior Director, Clinical Pharmacology and Pharmacometrics & Clinical Development Leader
Senior Director, Clinical Pharmacology and Pharmacometrics at Alnylam Pharmaceuticals
(December 2022 – Present)
Medical Science Liaison at Alnylam Pharmaceuticals
Associate Director, Medical Science Liaison - ATTR at Alnylam Pharmaceuticals
(August 2024 – Present)
What is Fanny Rabuel email address?
Email Fanny Rabuel at [email protected] and [email protected]. This email is the most updated Fanny Rabuel's email found in 2026.
How to contact Fanny Rabuel?
To contact Fanny Rabuel send an email to [email protected] or [email protected]. (updated on November 17, 2025)
What company does Fanny Rabuel work for?
Fanny Rabuel works for Alnylam Pharmaceuticals.
What is Fanny Rabuel's role at Alnylam Pharmaceuticals?
Fanny Rabuel is Rare Disease Business Lead
What industry does Fanny Rabuel work in?
Fanny Rabuel works in the Pharmaceuticals industry.
